Moderna Doses First Participants in Phase I Trial of mRNA-1469: A Breakthrough Pursuit for a Bundibugyo Ebola Vaccine
Executive Overview In a monumental step forward for global health security, biotechnology pioneer Moderna has officially dosed its first participants in a Phase I clinical trial evaluating mRNA-1469, a novel…